Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment

Bernard M. Ravina, S. C. Fagan, R. G. Hart, C. A. Hovinga, D. D. Murphy, Ted M Dawson, J. R. Marler

Research output: Contribution to journalArticle

Abstract

Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials. Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood-brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria. Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD. Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.

Original languageEnglish (US)
Pages (from-to)1234-1240
Number of pages7
JournalNeurology
Volume60
Issue number8
StatePublished - Apr 22 2003

Fingerprint

Neuroprotective Agents
Parkinson Disease
Clinical Trials
Drug Evaluation
Blood-Brain Barrier
Industry
Animal Models
Research Personnel
Safety
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ravina, B. M., Fagan, S. C., Hart, R. G., Hovinga, C. A., Murphy, D. D., Dawson, T. M., & Marler, J. R. (2003). Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. Neurology, 60(8), 1234-1240.

Neuroprotective agents for clinical trials in Parkinson's disease : A systematic assessment. / Ravina, Bernard M.; Fagan, S. C.; Hart, R. G.; Hovinga, C. A.; Murphy, D. D.; Dawson, Ted M; Marler, J. R.

In: Neurology, Vol. 60, No. 8, 22.04.2003, p. 1234-1240.

Research output: Contribution to journalArticle

Ravina, BM, Fagan, SC, Hart, RG, Hovinga, CA, Murphy, DD, Dawson, TM & Marler, JR 2003, 'Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment', Neurology, vol. 60, no. 8, pp. 1234-1240.
Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM et al. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment. Neurology. 2003 Apr 22;60(8):1234-1240.
Ravina, Bernard M. ; Fagan, S. C. ; Hart, R. G. ; Hovinga, C. A. ; Murphy, D. D. ; Dawson, Ted M ; Marler, J. R. / Neuroprotective agents for clinical trials in Parkinson's disease : A systematic assessment. In: Neurology. 2003 ; Vol. 60, No. 8. pp. 1234-1240.
@article{bf5d548132aa43a485d4e6023ea6b36a,
title = "Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment",
abstract = "Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials. Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood-brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria. Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD. Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.",
author = "Ravina, {Bernard M.} and Fagan, {S. C.} and Hart, {R. G.} and Hovinga, {C. A.} and Murphy, {D. D.} and Dawson, {Ted M} and Marler, {J. R.}",
year = "2003",
month = "4",
day = "22",
language = "English (US)",
volume = "60",
pages = "1234--1240",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Neuroprotective agents for clinical trials in Parkinson's disease

T2 - A systematic assessment

AU - Ravina, Bernard M.

AU - Fagan, S. C.

AU - Hart, R. G.

AU - Hovinga, C. A.

AU - Murphy, D. D.

AU - Dawson, Ted M

AU - Marler, J. R.

PY - 2003/4/22

Y1 - 2003/4/22

N2 - Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials. Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood-brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria. Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD. Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.

AB - Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials. Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood-brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria. Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD. Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.

UR - http://www.scopus.com/inward/record.url?scp=0037461309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037461309&partnerID=8YFLogxK

M3 - Article

C2 - 12707423

AN - SCOPUS:0037461309

VL - 60

SP - 1234

EP - 1240

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -